JPWO2021186397A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021186397A5
JPWO2021186397A5 JP2022555955A JP2022555955A JPWO2021186397A5 JP WO2021186397 A5 JPWO2021186397 A5 JP WO2021186397A5 JP 2022555955 A JP2022555955 A JP 2022555955A JP 2022555955 A JP2022555955 A JP 2022555955A JP WO2021186397 A5 JPWO2021186397 A5 JP WO2021186397A5
Authority
JP
Japan
Prior art keywords
immune cell
seq
receptor
nucleic acid
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022555955A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518930A5 (https=
JP2023518930A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/052294 external-priority patent/WO2021186397A1/en
Publication of JP2023518930A publication Critical patent/JP2023518930A/ja
Publication of JPWO2021186397A5 publication Critical patent/JPWO2021186397A5/ja
Publication of JP2023518930A5 publication Critical patent/JP2023518930A5/ja
Pending legal-status Critical Current

Links

JP2022555955A 2020-03-18 2021-03-18 Gpc3 car-t細胞組成物、並びにそれを作製する方法及び使用する方法 Pending JP2023518930A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062991493P 2020-03-18 2020-03-18
US62/991,493 2020-03-18
US202063004827P 2020-04-03 2020-04-03
US63/004,827 2020-04-03
US202063043237P 2020-06-24 2020-06-24
US63/043,237 2020-06-24
PCT/IB2021/052294 WO2021186397A1 (en) 2020-03-18 2021-03-18 Gpc3 car-t cell compositions and methods of making and using the same

Publications (3)

Publication Number Publication Date
JP2023518930A JP2023518930A (ja) 2023-05-09
JPWO2021186397A5 true JPWO2021186397A5 (https=) 2024-03-29
JP2023518930A5 JP2023518930A5 (https=) 2024-03-29

Family

ID=77768047

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022555955A Pending JP2023518930A (ja) 2020-03-18 2021-03-18 Gpc3 car-t細胞組成物、並びにそれを作製する方法及び使用する方法

Country Status (5)

Country Link
US (1) US20230146706A1 (https=)
EP (1) EP4121516A4 (https=)
JP (1) JP2023518930A (https=)
CN (1) CN115667500B (https=)
WO (1) WO2021186397A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
JP7778081B2 (ja) * 2020-03-18 2025-12-01 ユーティレックス カンパニー リミテッド Il-18を分泌するgpc3 car-t細胞、並びにそれを作製する方法及び使用する方法
EP4308133A4 (en) 2021-03-17 2025-01-22 Myeloid Therapeutics, Inc. MANIPULATED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
WO2025183436A1 (ko) * 2024-02-27 2025-09-04 (주)이노베이션바이오 Gpc3을 표적으로 하는 키메릭 항원 수용체 및 cd276을 표적으로 하는 키메릭 항원 수용체를 발현하는 면역 이펙터 세포 및 이의 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1842540B (zh) * 2004-07-09 2012-07-04 中外制药株式会社 抗-磷脂酰肌醇蛋白聚糖3抗体
CN101068836B (zh) * 2004-10-26 2013-08-14 中外制药株式会社 糖链改变的抗磷脂酰肌醇聚糖3抗体
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
CN104140974B (zh) * 2013-05-08 2017-09-29 科济生物医药(上海)有限公司 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
JP2017529851A (ja) * 2014-09-26 2017-10-12 ベイラー カレッジ オブ メディスンBaylor College Of Medicine 養子免疫療法のためのグリピカン−3特異的キメラ抗原レセプター
CN105713881B (zh) * 2014-12-04 2019-12-06 科济生物医药(上海)有限公司 双靶向gpc3和asgpr1的转基因免疫效应细胞及其应用
US11376326B2 (en) * 2015-07-01 2022-07-05 Chugai Seiyaku Kabushiki Kaisha GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective
US20190262397A1 (en) * 2016-07-26 2019-08-29 Tessa Therapeutics Pte. Ltd. Chimeric antigen receptor
BR112019013947A2 (pt) * 2017-01-10 2020-02-11 Yamaguchi University Anticorpo, receptor de antígeno quimérico, célula imunocompetente, gene de anticorpo, vetor, célula hospedeira, método para detectar gpc3, e, kit para a detecção de gpc3.
JPWO2020017479A1 (ja) * 2018-07-17 2021-08-02 ノイルイミューン・バイオテック株式会社 抗gpc3一本鎖抗体を含むcar
EP3829312A4 (en) * 2018-08-04 2022-07-06 Abcyte Therapeutics Inc. MULTIFUNCTIONAL AND MULTI-TARGETING CAR SYSTEM AND METHODS OF USE
CN111116743B (zh) * 2018-10-30 2022-01-28 迈威(上海)生物科技股份有限公司 Hsp90抗体及其在抗真菌感染中的应用

Similar Documents

Publication Publication Date Title
JP2021000103A5 (https=)
JPWO2020180591A5 (https=)
JP2021520788A5 (https=)
JP2025032091A5 (https=)
JP2020513839A5 (https=)
JP2019516352A5 (https=)
FI3844267T3 (fi) Menetelmät kimeeristä antigeenireseptoria ilmentävien solujen valmistamiseksi
HRP20221348T1 (hr) Kimerni receptori i postupci njihove uporabe
JP2019523301A5 (https=)
JP2018538339A5 (https=)
JP2021530233A5 (https=)
JP2019515661A5 (https=)
RU2017105160A (ru) Лечение рака с помощью химерного антигенного рецептора к cd33
JP2017524367A5 (https=)
JP2017522879A5 (https=)
RU2017105161A (ru) Лечение рака с использованием химерного антигенного рецептора cll-1
JP2018527014A5 (https=)
JPWO2019200007A5 (https=)
JPWO2016028896A5 (https=)
RU2019128921A (ru) Антитело к il-13ra2 и его применение
JP2020500903A5 (https=)
JPWO2021186397A5 (https=)
JPWO2020018695A5 (https=)
JPWO2020261231A5 (https=)
JPWO2021186395A5 (https=)